01Use the coenzyme name rather than a peptide description

ChEBI identifies NAD+ as the oxidised form of nicotinamide adenine dinucleotide and classifies it as a coenzyme involved in redox reactions. Its structure is a nucleotide-based entity, not an amino-acid sequence.ChEBI — NAD+ chemical entity CHEBI:15846 (opens in a new tab)

The supplied report explicitly describes oxidised beta-nicotinamide adenine dinucleotide as a non-peptide coenzyme. Its identity comparison is against a beta-NAD+ reference, and it separately lists NADH and ADP-ribose measurements.Supplied NAD+ 1000 mg report (opens in a new tab)

Those names should stay distinct in a reading note. A finding about a related chemical species does not become a finding about NAD+ simply because both appear on the same analytical report.

Chemical records may represent particular charge or protonation states. When comparing formulae, first establish the represented form rather than treating every apparent formula difference as proof of a different commercial ingredient.

02Separate the supplied intervention from the measured metabolite

Martens and colleagues’ 2018 placebo-controlled crossover study tested nicotinamide riboside, abbreviated NR, in healthy middle-aged and older adults. It reported increased blood cellular NAD+ after the NR intervention.Martens and colleagues — Chronic nicotinamide riboside supplementation in older adults (opens in a new tab)

The result belongs to a precursor study: the administered material and the measured coenzyme were different entities. Writing that participants received NAD+ would misdescribe the experiment.

This distinction is useful even when the direction of a biomarker change looks favourable. Evidence that one intervention raises a metabolite does not show that every route to that metabolite has the same distribution, tolerability or clinical effects.

03What a direct NAD+ pilot can establish

Grant and colleagues’ 2019 pilot followed plasma and urine metabolites during and after an intravenous NAD+ intervention. It included eleven men: eight in the NAD+ group and three saline controls, with measurements over eight hours.Grant and colleagues — Human plasma and urine NAD+ metabolome pilot (opens in a new tab)

The study reported changes in circulating and excreted metabolites. These are short-term disposition observations; the study was not a controlled demonstration of longer lifespan, restored cognition or improved physical performance.Grant and colleagues — Human plasma and urine NAD+ metabolome pilot (opens in a new tab)

A plasma concentration cannot by itself identify how much intact material entered a particular tissue or cellular compartment. When authors infer a possible fate from the pattern of metabolites, keep that interpretation separate from a directly measured tissue result.

No adverse events were observed during the reported infusion period. Eight exposed participants and brief observation do not settle uncommon or longer-term risks, and the result should not be broadened into a general safety guarantee.Grant and colleagues — Human plasma and urine NAD+ metabolome pilot (opens in a new tab)

04Organise NAD+ research without borrowing outcomes

Begin an evidence map with separate entries for direct NAD+, NR and any other precursor. Add the actual biological sample measured, such as blood cells or plasma, beside each outcome.

Next distinguish a biochemical result from a functional one. An increase in a measured coenzyme pool may justify a later clinical question, but the desired improvement still needs its own endpoint and comparison.

Finally, connect a supplied material only to documentation that identifies that material. The Novum report addresses the submitted sample’s chemical attributes; it does not demonstrate that the sample reproduces a clinical study formulation or outcome.

This approach leaves room for new findings without allowing a large, diverse NAD-related literature to look like one continuous body of evidence for a single product.